Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
Phase 2
Not yet recruiting
- Conditions
- Resectable Locally Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Penpulimab+AnlotinibDrug: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/DocetaxelDrug: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2021-04-15
- Target Recruit Count
- 90
- Registration Number
- NCT04846634
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
Not Applicable
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Procedure: Type of omentectomy
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-05-10
- Target Recruit Count
- 950
- Registration Number
- NCT04843215
- Locations
- 🇨🇳
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
Phase 2
- Conditions
- Refractory or Recurrent Neuroblastoma in Children
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-04-13
- Target Recruit Count
- 27
- Registration Number
- NCT04842526
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- First-line TreatmentNon-small Cell Lung Cancer Metastatic
- Interventions
- Biological: CIK cells injection
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 156
- Registration Number
- NCT04836728
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Phase 2
- Conditions
- Resectable Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-04-08
- Target Recruit Count
- 30
- Registration Number
- NCT04834986
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute and Hospital, Tianjin, Tianjin, China
SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: SHR6390+anatrozole
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-04-12
- Target Recruit Count
- 20
- Registration Number
- NCT04836520
- Locations
- 🇨🇳
TianJin Medical University Cancer Institute and Hospital, Tianjin, China
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-05-11
- Target Recruit Count
- 65
- Registration Number
- NCT04828395
- Locations
- 🇨🇳
Liu ningbo, Tianjin, China
Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments
Not Applicable
Not yet recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Device: DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-12
- Target Recruit Count
- 60
- Registration Number
- NCT04825925
Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2021-05-25
- Target Recruit Count
- 39
- Registration Number
- NCT04814485
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
Phase 2
- Conditions
- Adenocarcinoma of Esophagogastric JunctionPembrolizumabNeoadjuvant Chemotherapy
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2021-03-24
- Target Recruit Count
- 30
- Registration Number
- NCT04813523
- Locations
- 🇨🇳
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath